GlaxoSmithKline Pleads Guilty illegal Drug Marketing, to Pay $3B Fine – ValueWalk Premium
GlaxoSmithKline

GlaxoSmithKline Pleads Guilty illegal Drug Marketing, to Pay $3B Fine

The biggest player of the pharmaceutical industry, GlaxoSmithKline plc (NYSE:GSK), makes the biggest settlement of healthcare fraud in US trial history. This brings an end to a long-running case against the pharmaceutical giant that was under investigation for many years now. FDA, FBI and Department of Health and Human Services had been probing the matter.

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
0